FLAURA-2 Overall Survival Data and Identifying Patient Populations Benefitting from Upfront Combination Therapy

New data on multiple targeted agents and evolving diagnostic frameworks highlight progress in classifying and treating EGFR PACC–mutated NSCLC.

Edward B. Garon, MD, MS, details how frontline therapy shapes sequencing in relapsed/refractory EGFR-mutated non–small cell lung cancer.

Five Huntsman Cancer Institute at the University of Utah colleagues earned endowed chair appointments, including new appointments.

The CHMP recommended EU approval of T-DXd plus pertuzumab as first-line therapy for HER2-positive metastatic breast cancer,

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The CHMP has recommended the approval of sacituzumab govitecan/pembrolizumab for treatment-naive, PD-L1-positive metastatic TNBC in the European Union.

Overall survival was the sole US primary end point of the phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab and was not met.

Watch a highlight reel of breast cancer data from ASCO 2026 that experts anticipate will have the biggest impact on the field.